Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

【24h】

Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

机译：根据现代代理时代的分子亚型，在HER2-VE晚期乳腺癌（ABC）患者（PTS）中的无进展生存（PFS）和整体存活（OS）。 GIM-13 Ambra研究结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
专利

1. Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：根据现代代理时代的分子亚型，在HER2-VE晚期乳腺癌（ABC）患者（PTS）中的无进展生存（PFS）和整体存活（OS）。 GIM-13 Ambra研究结果
2. NAB-PACLITAXEL (NAB-P) IN HER2-VE ADVANCED BREAST CANCER (ABC) PATIENTS (PTS): FOCUS ON LUMINAL CANCERS. RESULTS FROM GIM13-AMBRA STUDY [J] . Cazzaniga Marina Elena, Mustacchi Giorgio, Bria Emilio, The Breast : . 2017 ,第Suppla1期

机译：Nab-Paclitaxel（Nab-P）在Her2-VE晚期乳腺癌（ABC）患者（PTS）中：专注于腔癌。 GIM13-AMBRA研究结果
3. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies [J] . Cazzaniga M.E., Verusio C., Ciccarese M., Breast care . 2020 ,第1期

机译：在人力资源+ /海拔乳腺癌患者中仍然存在单独治疗的作用吗？在实际环境中分析高剂量氟斯特提治疗患者两种数据集的结果：EVA和GIM-13 AMBRA研究
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Integrated Molecular and Histologic Subtypes in Breast Cancer Risk and Survival [D] . Williams, Lindsay Almquist 2017

机译：综合分子和组织学亚型在乳腺癌的风险和生存中。
6. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies [O] . Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, 2020

机译：在人力资源+ /海拔乳腺癌患者中仍然存在单独治疗的作用吗？在实际环境中分析高剂量氟斯特提治疗患者两种数据集的结果：EVA和GIM-13 AMBRA研究
7. Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial [O] . Y.-S. Lu, A. Bardia, R.V. Vázquez, 2019

机译：更新了先进患者（PTS）的整体生存（OS）和生活质量（PTS），其先进的乳腺癌（ABC）接受核核苷酸（肋骨）或安慰剂（PBO）加上Goserelin和MonaleSea中的非甾体芳香酶抑制剂（NSAI） -7（ML-7）试验

Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

著录项

相似文献

相关主题

期刊订阅